Mitochondria and cell bioenergetics: Increasingly recognized components and a possible etiologic cause of alzheimer's disease

Antioxidants and Redox Signaling

Volumn 16, Issue 12, 2012, Pages 1434-1455

  Swerdlow, Russell H ^a  

^a UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; ANTIOXIDANT; BETA SECRETASE; CARBONYL CYANIDE CHLOROPHENYLHYDRAZONE; CYCLOPHILIN D; DEOXYGLUCOSE; MANGANESE SUPEROXIDE DISMUTASE; MITOCHONDRIAL DNA; NERVE GROWTH FACTOR; PROSTAGLANDIN SYNTHASE; SODIUM AZIDE;

AEROBIC METABOLISM; ALZHEIMER DISEASE; AMYLOIDOSIS; CELL ENERGY; CELL FUNCTION; CYBRID; DATA ANALYSIS; ELECTRON MICROSCOPY; ENDOPHENOTYPE; GENE INACTIVATION; HUMAN; HYPOTHESIS; MEDICAL RECORD; MITOCHONDRIAL ENERGY TRANSFER; NONHUMAN; NUCLEOTIDE SEQUENCE; OXYGEN CONSUMPTION; PRIORITY JOURNAL; REVIEW;

ALZHEIMER DISEASE; ANIMALS; ENERGY METABOLISM; HUMANS; MITOCHONDRIA;

EID: 84860210262     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2011.4149     Document Type: Review

References (306)

1. Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18: S1-2, 1997.
2. Albert MS, Dekosky ST, Dickson D, Dubois B, Feldman HH, Fox NC, Gamst A, Holtzman DM, Jagust WJ, Petersen RC, Snyder PJ, Carrillo MC, Thies B, and Phelps CH. The diagnosis of mild cognitive impairment due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 270-279, 2011.
3. Allaman I, Belanger M, and Magistretti PJ. Astrocyte-neuron metabolic relationships: For better and for worse. Trends Neurosci 34: 76-87, 2011.
4. Allaman I, Gavillet M, Belanger M, Laroche T, Viertl D, Lashuel HA, and Magistretti PJ. Amyloid-beta aggregates cause alterations of astrocytic metabolic phenotype: Impact on neuronal viability. J Neurosci 30: 3326-3338, 2010.
5. Alvarez V, Corao AI, Alonso-Montes C, Sanchez-Ferrero E, De Mena L, Morales B, Garcia-Castro M, and Coto E. Mitochondrial transcription factor A (TFAM) gene variation and risk of late-onset Alzheimer's disease. J Alzheimers Dis 13: 275-280, 2008. (Pubitemid 352039031)
6. Alzheimer A. Uber eine eigenartige Erkrankung der Hirnrinde. Allg Z Psychiat Psych-Gerichtl Med 64: 146-148, 1907.
7. Anandatheerthavarada HK, Biswas G, Robin MA, and Avadhani NG. Mitochondrial targeting and a novel transmembrane arrest of Alzheimer's amyloid precursor protein impairs mitochondrial function in neuronal cells. J Cell Biol 161: 41-54, 2003. (Pubitemid 36459078)
8. Anandatheerthavarada HK and Devi L. Amyloid precursor protein and mitochondrial dysfunction in Alzheimer's disease. Neuroscientist 13: 626-638, 2007. (Pubitemid 350077307)
9. Baloyannis SJ. Mitochondrial alterations in Alzheimer's disease. J Alzheimers Dis 9: 119-126, 2006. (Pubitemid 44088243)
10. Bassett SS, Avramopoulos D, and Fallin D. Evidence for parent of origin effect in late-onset Alzheimer disease. Am J Med Genet 114: 679-686, 2002.
11. Beal MF. Aging, energy, and oxidative stress in neurodegenerative diseases. Ann Neurol 38: 357-366, 1995.
12. Bekris LM, Galloway NM, Montine TJ, Schellenberg GD, and Yu CE. APOE mRNA and protein expression in postmortem brain are modulated by an extended haplotype structure. Am J Med Genet B Neuropsychiatr Genet 153B: 409-417, 2009.
13. Bekris LM, Millard SP, Galloway NM, Vuletic S, Albers JJ, Li G, Galasko DR, DeCarli C, Farlow MR, Clark CM, Quinn JF, Kaye JA, Schellenberg GD, Tsuang D, Peskind ER, and Yu CE. Multiple SNPs within and surrounding the apolipoprotein E gene influence cerebrospinal fluid apolipoprotein E protein levels. J Alzheimers Dis 13: 255-266, 2008. (Pubitemid 352039030)
14. Belin AC, Bjork BF, Westerlund M, Galter D, Sydow O, Lind C, Pernold K, Rosvall L, Hakansson A, Winblad B, Nissbrandt H, Graff C, and Olson L. Association study of two genetic variants in mitochondrial transcription factor A (TFAM) in Alzheimer's and Parkinson's disease. Neurosci Lett 420: 257-262, 2007. (Pubitemid 46856016)
15. Berti V, Mosconi L, Glodzik L, Li Y, Murray J, De Santi S, Pupi A, Tsui W, and De Leon MJ. Structural brain changes in normal individuals with a maternal history of Alzheimer's. Neurobiol Aging: Epub ahead of print, 2011.
16. Bijur GN, Davis RE, and Jope RS. Rapid activation of heat shock factor-1 DNA binding by H2O2 and modulation by glutathione in human neuroblastoma and Alzheimer's disease cybrid cells. Brain Res Mol Brain Res 71: 69-77, 1999. (Pubitemid 29320057)
17. Bindoff LA, Birch-Machin M, Cartlidge NE, Parker WD, Jr., and Turnbull DM. Mitochondrial function in Parkinson's disease. Lancet 2: 49, 1989. (Pubitemid 19158192)
18. Blanchard BJ, Park T, Fripp WJ, Lerman LS, and Ingram VM. A mitochondrial DNA deletion in normally aging and in Alzheimer brain tissue. Neuroreport 4: 799-802, 1993. (Pubitemid 23190922)
19. Blass JP, Baker AC, Ko L, and Black RS. Induction of Alzheimer antigens by an uncoupler of oxidative phosphorylation. Arch Neurol 47: 864-869, 1990. (Pubitemid 20251716)
20. Blass JP and Gibson GE. Nonneural markers in Alzheimer disease. Alzheimer Dis Assoc Disord 6: 205-224, 1992. (Pubitemid 23089766)
21. Blass JP, Gibson GE, and Hoyer S. The role of the metabolic lesion in Alzheimer's disease. J Alzheimers Dis 4: 225-232, 2002. (Pubitemid 35006054)
22. Blass JP and Zemcov A. Alzheimer's disease. A metabolic systems degeneration? Neurochem Pathol 2: 103-114, 1984.
23. Boissiere F, Lehericy S, Strada O, Agid Y, and Hirsch EC. Neurotrophin receptors and selective loss of cholinergic neurons in Alzheimer disease. Mol Chem Neuropathol 28: 219-223, 1996. (Pubitemid 26275071)
24. Bosetti F, Brizzi F, Barogi S, Mancuso M, Siciliano G, Tendi EA, Murri L, Rapoport SI, and Solaini G. Cytochrome c oxidase and mitochondrial F1F0-ATPase (ATP synthase) activities in platelets and brain from patients with Alzheimer's disease. Neurobiol Aging 23: 371-376, 2002. (Pubitemid 34312019)
25. Bowen DM, White P, Spillane JA, Goodhardt MJ, Curzon G, Iwangoff P, Meier-Ruge W, and Davison AN. Accelerated ageing or selective neuronal loss as an important cause of dementia? Lancet 1: 11-14, 1979. (Pubitemid 9084463)
26. Brand MD, Affourtit C, Esteves TC, Green K, Lambert AJ, Miwa S, Pakay JL, and Parker N. Mitochondrial superoxide: Production, biological effects, and activation of uncoupling proteins. Free Radic Biol Med 37: 755-767, 2004. (Pubitemid 39078548)
27. Brody DL, Magnoni S, Schwetye KE, Spinner ML, Esparza TJ, Stocchetti N, Zipfel GJ, and Holtzman DM. Amyloidbeta dynamics correlate with neurological status in the injured human brain. Science 321: 1221-1224, 2008.
28. Brown AM, Sheu RK, Mohs R, Haroutunian V, and Blass JP. Correlation of the clinical severity of Alzheimer's disease with an aberration in mitochondrial DNA (mtDNA). J Mol Neurosci 16: 41-48, 2001. (Pubitemid 32402344)
29. Bunn CL, Wallace DC, and Eisenstadt JM. Cytoplasmic inheritance of chloramphenicol resistance in mouse tissue culture cells. Proc Natl Acad Sci USA 71: 1681-1685, 1974.
30. Canevari L, Clark JB, and Bates TE. beta-Amyloid fragment 25-35 selectively decreases complex IV activity in isolated mitochondria. FEBS Lett 457: 131-134, 1999. (Pubitemid 29387424)
31. Cardoso SM, Proenca MT, Santos S, Santana I, and Oliveira CR. Cytochrome c oxidase is decreased in Alzheimer's disease platelets. Neurobiol Aging 25: 105-110, 2004. (Pubitemid 37522198)
32. Cardoso SM, Santana I, Swerdlow RH, and Oliveira CR. Mitochondria dysfunction of Alzheimer's disease cybrids enhances Abeta toxicity. J Neurochem 89: 1417-1426, 2004. (Pubitemid 38802663)
33. Cardoso SM, Santos S, Swerdlow RH, and Oliveira CR. Functional mitochondria are required for amyloid betamediated neurotoxicity. FASEB J 15: 1439-1441, 2001.
34. Carrieri G, Bonafe M, De Luca M, Rose G, Varcasia O, Bruni A, Maletta R, Nacmias B, Sorbi S, Corsonello F, Feraco E, Andreev KF, Yashin AI, Franceschi C, De and Benedictis G. Mitochondrial DNA haplogroups and APOE4 allele are non-independent variables in sporadic Alzheimer's disease. Hum Genet 108: 194-198, 2001. (Pubitemid 32293664)
35. Casley CS, Canevari L, Land JM, Clark JB, and Sharpe MA. Beta-amyloid inhibits integrated mitochondrial respiration and key enzyme activities. J Neurochem 80: 91-100, 2002. (Pubitemid 34614581)
36. Caspersen C, Wang N, Yao J, Sosunov A, Chen X, Lustbader JW, Xu HW, Stern D, McKhann G, and Yan SD. Mitochondrial Abeta: A potential focal point for neuronal metabolic dysfunction in Alzheimer's disease. FASEB J 19: 2040-2041, 2005. (Pubitemid 41759758)
37. Cassarino DS, Swerdlow RH, Parks JK, Parker WD, Jr., and Bennett JP, Jr. Cyclosporin A increases resting mitochondrial membrane potential in SY5Y cells and reverses the depressed mitochondrial membrane potential of Alzheimer's disease cybrids. Biochem Biophys Res Commun 248: 168-173, 1998. (Pubitemid 28418206)
38. Castellani R, Hirai K, Aliev G, Drew KL, Nunomura A, Takeda A, Cash AD, Obrenovich ME, Perry G, and Smith MA. Role of mitochondrial dysfunction in Alzheimer's disease. J Neurosci Res 70: 357-360, 2002. (Pubitemid 35222373)
39. Cecarini V, Gee J, Fioretti E, Amici M, Angeletti M, Eleuteri AM, and Keller JN. Protein oxidation and cellular homeostasis: Emphasis on metabolism. Biochim Biophys Acta 1773: 93-104, 2007. (Pubitemid 46123609)
40. Chagnon P, Betard C, Robitaille Y, Cholette A, and Gauvreau D. Distribution of brain cytochrome oxidase activity in various neurodegenerative diseases. Neuroreport 6: 711-715, 1995.
41. Chagnon P, Gee M, Filion M, Robitaille Y, Belouchi M, and Gauvreau D. Phylogenetic analysis of the mitochondrial genome indicates significant differences between patients with Alzheimer disease and controls in a French-Canadian founder population. Am J Med Genet 85: 20-30, 1999. (Pubitemid 29256801)
42. Chandrasekaran K, Giordano T, Brady DR, Stoll J, Martin LJ, and Rapoport SI. Impairment in mitochondrial cytochrome oxidase gene expression in Alzheimer disease. Brain Res Mol Brain Res 24: 336-340, 1994. (Pubitemid 24202871)
43. Chandrasekaran K, Hatanpaa K, Brady DR, and Rapoport SI. Evidence for physiological down-regulation of brain oxidative phosphorylation in Alzheimer's disease. Exp Neurol 142: 80-88, 1996. (Pubitemid 26381382)
44. Chang S, ran Ma T, Miranda RD, Balestra ME, Mahley RW, and Huang Y. Lipid-and receptor-binding regions of apolipoprotein E4 fragments act in concert to cause mitochondrial dysfunction and neurotoxicity. Proc Natl Acad Sci USA 102: 18694-18699, 2005. (Pubitemid 43011288)
45. Chang SW, Zhang D, Chung HD, and Zassenhaus HP. The frequency of point mutations in mitochondrial DNA is elevated in the Alzheimer's brain. Biochem Biophys Res Commun 273: 203-208, 2000. (Pubitemid 30426887)
46. Chen HK, Ji ZS, Dodson SE, Miranda RD, Rosenblum CI, Reynolds IJ, Freedman SB, Weisgraber KH, Huang Y, and Mahley RW. Apolipoprotein E4 domain interaction mediates detrimental effects on mitochondria and is a potential therapeutic target for Alzheimer disease. J Biol Chem 286: 5215-5221, 2011.
47. Chen L, Yoo SE, Na R, Liu Y, and Ran Q. Cognitive impairment and increased Abeta levels induced by paraquat exposure are attenuated by enhanced removal of mitochondrial H(2)O(2). Neurobiol Aging [Epub ahead of print, 2011].
48. Chinnery PF, Taylor GA, Howell N, Andrews RM, Morris CM, Taylor RW, McKeith IG, Perry RH, Edwardson JA, and Turnbull DM. Mitochondrial DNA haplogroups and susceptibility to AD and dementia with Lewy bodies. Neurology 55: 302-304, 2000. (Pubitemid 30604638)
49. Chomyn A, Lai ST, Shakeley R, Bresolin N, Scarlato G, and Attardi G. Platelet-mediated transformation of mtDNAless human cells: analysis of phenotypic variability among clones from normal individuals-and complementation behavior of the tRNALys mutation causing myoclonic epilepsy and ragged red fibers. Am J Hum Genet 54: 966-974, 1994.
50. Clayton DA. Transcription and replication of mitochondrial DNA. Hum Reprod 15 Suppl 2: 11-17, 2000.
51. Cole G, Dobkins KR, Hansen LA, Terry RD, and Saitoh T. Decreased levels of protein kinase C in Alzheimer brain. Brain Res 452: 165-174, 1988.
52. Corder EH, Saunders AM, Strittmatter WJ, Schmechel DE, Gaskell PC, Small GW, Roses AD, Haines JL, and Pericak-Vance MA. Gene dose of apolipoprotein E type 4 allele and the risk of Alzheimer's disease in late onset families. Science 261: 921-923, 1993. (Pubitemid 23275809)
53. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, Beal MF, and Wallace DC. Mitochondrial DNA deletions in human brain: Regional variability and increase with advanced age. Nat Genet 2: 324-329, 1992.
54. Corral-Debrinski M, Horton T, Lott MT, Shoffner JM, McKee AC, Beal MF, Graham BH, and Wallace DC. Marked changes in mitochondrial DNA deletion levels in Alzheimer brains. Genomics 23: 471-476, 1994. (Pubitemid 24308270)
55. Coskun PE, Beal MF, and Wallace DC. Alzheimer's brains harbor somatic mtDNA control-region mutations that suppress mitochondrial transcription and replication. Proc Natl Acad Sci USA 101: 10726-10731, 2004. (Pubitemid 38955810)
56. Coskun PE,Wyrembak J, Derbereva O, Melkonian G, Doran E, Lott IT, Head E, Cotman CW, and Wallace DC. Systemic mitochondrial dysfunction and the etiology of Alzheimer's disease and Down syndrome dementia. J Alzheimers Dis 20: S293-310, 2010.
57. Cotman CW. Apoptosis decision cascades and neuronal degeneration in Alzheimer's disease. Neurobiol Aging 19: S29-32, 1998. (Pubitemid 28178934)
58. Cottrell DA, Blakely EL, JohnsonMA, Ince PG, and Turnbull DM. Mitochondrial enzyme-deficient hippocampal neurons and choroidal cells in AD. Neurology 57: 260-264, 2001. (Pubitemid 32667359)
59. Cottrell DA, Borthwick GM, Johnson MA, Ince PG, and Turnbull DM. The role of cytochrome c oxidase deficient hippocampal neurones in Alzheimer's disease. Neuropathol Appl Neurobiol 28: 390-396, 2002. (Pubitemid 35279072)
60. Counts SE and Mufson EJ. The role of nerve growth factor receptors in cholinergic basal forebrain degeneration in prodromal Alzheimer disease. J Neuropathol Exp Neurol 64: 263-272, 2005. (Pubitemid 40489553)
61. Crouch PJ, Blake R, Duce JA, Ciccotosto GD, Li QX, Barnham KJ, Curtain CC, Cherny RA, Cappai R, Dyrks T, Masters CL, and Trounce IA. Copper-dependent inhibition of human cytochrome c oxidase by a dimeric conformer of amyloid-beta1-42. J Neurosci 25: 672-679, 2005.
62. Curti D, Rognoni F, Gasparini L, Cattaneo A, Paolillo M, Racchi M, Zani L, Bianchetti A, Trabucchi M, Bergamaschi S, and Govoni S. Oxidative metabolism in cultured fibroblasts derived from sporadic Alzheimer's disease (AD) patients. Neurosci Lett 236: 13-16, 1997. (Pubitemid 27492067)
63. Davis JN, Hunnicutt EJ, Jr., and Chisholm JC. A mitochondrial bottleneck hypothesis of Alzheimer's disease. Mol Med Today 1: 240-247, 1995.
64. Davis RE, Miller S, Herrnstadt C, Ghosh SS, Fahy E, Shinobu LA, Galasko D, Thal LJ, Beal MF, Howell N, and Parker WD, Jr. Mutations in mitochondrial cytochrome c oxidase genes segregate with late-onset Alzheimer disease. Proc Natl Acad Sci USA 94: 4526-4531, 1997. (Pubitemid 27194275)
65. de la Monte SM, Luong T, Neely TR, Robinson D, and Wands JR. Mitochondrial DNA damage as a mechanism of cell loss in Alzheimer's disease. Lab Invest 80: 1323-1335, 2000. (Pubitemid 30637072)
66. de la Monte SM, Sohn YK, and Wands JR. Correlates of p53-and Fas (CD95)-mediated apoptosis in Alzheimer's disease. J Neurol Sci 152: 73-83, 1997. (Pubitemid 27469712)
67. de Leon MJ, Ferris SH, George AE, Christman DR, Fowler JS, Gentes C, Reisberg B, Gee B, Emmerich M, Yonekura Y, Brodie J, Kricheff, II, and Wolf AP. Positron emission tomographic studies of aging and Alzheimer disease. AJNR Am J Neuroradiol 4: 568-571, 1983.
68. De Sarno P, Bijur GN, Lu R, Davis RE, and Jope RS. Alterations in muscarinic receptor-coupled phosphoinositide hydrolysis and AP-1 activation in Alzheimer's disease cybrid cells. Neurobiol Aging 21: 31-38, 2000. (Pubitemid 30224783)
69. Debette S, Wolf PA, Beiser A, Au R, Himali JJ, Pikula A, Auerbach S, Decarli C, and Seshadri S. Association of parental dementia with cognitive and brain MRI measures in middle-aged adults. Neurology 73: 2071-2078, 2009.
70. Desjardins P, de Muys JM, and Morais R. An established avian fibroblast cell line without mitochondrial DNA. Somat Cell Mol Genet 12: 133-139, 1986. (Pubitemid 16131556)
71. Desjardins P, Frost E, and Morais R. Ethidium bromideinduced loss of mitochondrial DNA from primary chicken embryo fibroblasts. Mol Cell Biol 5: 1163-1169, 1985. (Pubitemid 15110308)
72. Devi L, Prabhu BM, Galati DF, Avadhani NG, and Anandatheerthavarada HK. Accumulation of amyloid precursor protein in the mitochondrial import channels of human Alzheimer's disease brain is associated with mitochondrial dysfunction. J Neurosci 26: 9057-9068, 2006. (Pubitemid 44319397)
73. Diana A, Simic G, Sinforiani E, Orru N, Pichiri G, and Bono G. Mitochondria morphology and DNA content upon sublethal exposure to beta-amyloid(1-42) peptide. Coll Antropol 32: 51-58, 2008.
74. Dragicevic N, Mamcarz M, Zhu Y, Buzzeo R, Tan J, Arendash GW, and Bradshaw PC. Mitochondrial amyloid-beta levels are associated with the extent of mitochondrial dysfunction in different brain regions and the degree of cognitive impairment in Alzheimer's transgenic mice. J Alzheimers Dis 20: S535-550, 2010.
75. Du H, Guo L, Fang F, Chen D, Sosunov AA, McKhann GM, Yan Y, Wang C, Zhang H, Molkentin JD, Gunn-Moore FJ, Vonsattel JP, Arancio O, Chen JX, and Yan SD. Cyclophilin D deficiency attenuates mitochondrial and neuronal perturbation and ameliorates learning and memory in Alzheimer's disease. Nat Med 14: 1097-1105, 2008.
76. Du H, Guo L, Yan S, Sosunov AA, McKhann GM, and Yan SS. Early deficits in synaptic mitochondria in an Alzheimer's disease mouse model. Proc Natl Acad Sci USA 107: 18670-18675, 2010.
77. Duara R, Lopez-Alberola RF, Barker WW, Loewenstein DA, Zatinsky M, Eisdorfer CE, and Weinberg GB. A comparison of familial and sporadic Alzheimer's disease. Neurology 43: 1377-1384, 1993. (Pubitemid 23213814)
78. Dumont M, Wille E, Stack C, Calingasan NY, Beal MF, and Lin MT. Reduction of oxidative stress, amyloid deposition, and memory deficit by manganese superoxide dismutase overexpression in a transgenic mouse model of Alzheimer's disease. FASEB J 23: 2459-2466, 2009.
79. Edland SD, Silverman JM, Peskind ER, Tsuang D, Wijsman E, and Morris JC. Increased risk of dementia in mothers of Alzheimer's disease cases: Evidence for maternal inheritance. Neurology 47: 254-256, 1996. (Pubitemid 26243893)
80. Edland SD, Tobe VO, Rieder MJ, Bowen JD, McCormick W, Teri L, Schellenberg GD, Larson EB, Nickerson DA, and Kukull WA. Mitochondrial genetic variants and Alzheimer disease: A case-control study of the T4336C and G5460A variants. Alzheimer Dis Assoc Disord 16: 1-7, 2002. (Pubitemid 34296616)
81. Egensperger R, Kosel S, Schnopp NM,Mehraein P, and Graeber MB. Association of the mitochondrial tRNA(A4336G) mutation with Alzheimer's and Parkinson's diseases. Neuropathol Appl Neurobiol 23: 315-321, 1997. (Pubitemid 27352842)
82. Ekstrand MI, Falkenberg M, Rantanen A, Park CB, Gaspari M, Hultenby K, Rustin P, Gustafsson CM, and Larsson NG. Mitochondrial transcription factor A regulates mtDNA copy number in mammals. Hum Mol Genet 13: 935-944, 2004. (Pubitemid 38628429)
83. Ephrussi B, Hottinger H, and Chimenes A. Action de l'acriflavine sur les levures, I: la mutation "petite clonie." Ann Inst Pasteur 76: 531, 1949.
84. Escobar-Khondiker M, Hollerhage M, Muriel MP, Champy P, Bach A, Depienne C, Respondek G, Yamada ES, Lannuzel A, Yagi T, Hirsch EC, Oertel WH, Jacob R, Michel PP, Ruberg M, and Hoglinger GU. Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons. J Neurosci 27: 7827-7837, 2007. (Pubitemid 47093824)
85. Evans DA, Funkenstein HH, Albert MS, Scherr PA, Cook NR, Chown MJ, Hebert LE, Hennekens CH, and Taylor JO. Prevalence of Alzheimer's disease in a community population of older persons. Higher than previously reported. JAMA 262: 2551-2556, 1989.
86. Fesahat F, Houshmand M, Panahi MS, Gharagozli K, and Mirzajani F. Do haplogroups H and U act to increase the penetrance of Alzheimer's disease? Cell Mol Neurobiol 27: 329-334, 2007. (Pubitemid 46763880)
87. Foster NL, Chase TN, Fedio P, Patronas NJ, Brooks RA, and Di Chiro G. Alzheimer's disease: Focal cortical changes shown by positron emission tomography. Neurology 33: 961-965, 1983. (Pubitemid 13030175)
88. Frackowiak RS, Pozzilli C, Legg NJ, Du Boulay GH, Marshall J, Lenzi GL, and Jones T. Regional cerebral oxygen supply and utilization in dementia. A clinical and physiological study with oxygen-15 and positron tomography. Brain 104: 753-778, 1981. (Pubitemid 12235670)
89. Friede RL. Enzyme histochemical studies of senile plaques. J Neuropathol Exp Neurol 24: 477-491, 1965.
90. Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE. Regional cerebral metabolic alterations in dementia of the Alzheimer type: Positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr 7: 590-598, 1983. (Pubitemid 13035941)
91. Fukui H, Diaz F, Garcia S, Moraes CT. Cytochrome c oxidase deficiency in neurons decreases both oxidative stress and amyloid formation in a mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 104: 14163-14168, 2007. (Pubitemid 350003352)
92. Fukuyama H, Ogawa M, Yamauchi H, Yamaguchi S, Kimura J, Yonekura Y, Konishi J. Altered cerebral energy metabolism in Alzheimer's disease: A PET study. J Nucl Med 35: 1-6, 1994. (Pubitemid 24018423)
93. Gabuzda D, Busciglio J, Chen LB, Matsudaira P, and Yankner BA. Inhibition of energy metabolism alters the processing of amyloid precursor protein and induces a potentially amyloidogenic derivative. J Biol Chem 269: 13623-13628, 1994. (Pubitemid 24206141)
94. Gasparini L, Racchi M, Benussi L, Curti D, Binetti G, Bianchetti A, Trabucchi M, and Govoni S. Effect of energy shortage and oxidative stress on amyloid precursor protein metabolism in COS cells. Neurosci Lett 231: 113-117, 1997. (Pubitemid 27386502)
95. Ghosh SS, Swerdlow RH, Miller SW, Sheeman B, Parker WD, Jr., and Davis RE. Use of cytoplasmic hybrid cell lines for elucidating the role of mitochondrial dysfunction in Alzheimer's disease and Parkinson's disease. Ann NY Acad Sci 893: 176-191, 1999. (Pubitemid 30038075)
96. Gibson GE, Nielsen P, Sherman KA, and Blass JP. Diminished mitogen-induced calcium uptake by lymphocytes from Alzheimer patients. Biol Psychiatry 22: 1079-1086, 1987. (Pubitemid 17138303)
97. Gibson GE, Sheu KF, Blass JP, Baker A, Carlson KC, Harding B, and Perrino P. Reduced activities of thiaminedependent enzymes in the brains and peripheral tissues of patients with Alzheimer's disease. Arch Neurol 45: 836-840, 1988.
98. Giles RE, Blanc H, Cann HM, and Wallace DC. Maternal inheritance of human mitochondrial DNA. Proc Natl Acad Sci USA 77: 6715-6719, 1980. (Pubitemid 11163470)
99. Glenner GG and Wong CW. Alzheimer's disease: Initial report of the purification and characterization of a novel cerebrovascular amyloid protein. Biochem Biophys Res Commun 120: 885-890, 1984. (Pubitemid 14104991)
100. Goate A, Chartier-Harlin MC, Mullan M, Brown J, Crawford F, Fidani L, Giuffra L, Haynes A, Irving N, James L, et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease. Nature 349: 704-706, 1991. (Pubitemid 21912142)
101. Griffin RJ, Moloney A, Kelliher M, Johnston JA, Ravid R, Dockery P, O'Connor R, and O'Neill C. Activation of Akt/PKB, increased phosphorylation of Akt substrates and loss and altered distribution of Akt and PTEN are features of Alzheimer's disease pathology. J Neurochem 93: 105-117, 2005. (Pubitemid 40463520)
102. Gunther C, von Hadeln K, Muller-Thomsen T, Alberici A, Binetti G, Hock C, Nitsch RM, Stoppe G, Reiss J, Gal A, and Finckh U. Possible association of mitochondrial transcription factor A (TFAM) genotype with sporadic Alzheimer disease. Neurosci Lett 369: 219-223, 2004. (Pubitemid 39298912)
103. Haan MN. Therapy Insight: Type 2 diabetes mellitus and the risk of late-onset Alzheimer's disease. Nat Clin Pract Neurol 2: 159-166, 2006.
104. Hamblet NS and Castora FJ. Elevated levels of the Kearns-Sayre syndrome mitochondrial DNA deletion in temporal cortex of Alzheimer's patients. Mutat Res 379: 253-262, 1997. (Pubitemid 27450545)
105. Hansson CA, Frykman S, Farmery MR, Tjernberg LO, Nilsberth C, Pursglove SE, Ito A, Winblad B, Cowburn RF, Thyberg J, and Ankarcrona M. Nicastrin, presenilin, APH-1, and PEN-2 form active gamma-secretase complexes in mitochondria. J Biol Chem 279: 51654-51660, 2004. (Pubitemid 40017916)
106. Hansson Petersen CA, Alikhani N, Behbahani H, Wiehager B, Pavlov PF, Alafuzoff I, Leinonen V, Ito A, Winblad B, Glaser E, and Ankarcrona M. The amyloid beta-peptide is imported into mitochondria via the TOM import machinery and localized to mitochondrial cristae. Proc Natl Acad Sci USA 105: 13145-13150, 2008.
107. Hardy J and Allsop D. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. Trends Pharmacol Sci 12: 383-388, 1991.
108. Hardy J and Selkoe DJ. The amyloid hypothesis of Alzheimer's disease: Progress and problems on the road to therapeutics. Science 297: 353-356, 2002. (Pubitemid 34790756)
109. Hardy JA and Higgins GA. Alzheimer's disease: The amyloid cascade hypothesis. Science 256: 184-185, 1992.
110. Harold D, Abraham R, Hollingworth P, Sims R, Gerrish A, Hamshere ML, Pahwa JS, Moskvina V, Dowzell K, Williams A, Jones N, Thomas C, Stretton A, Morgan AR, Lovestone S, Powell J, Proitsi P, Lupton MK, Brayne C, Rubinsztein DC, Gill M, Lawlor B, Lynch A, Morgan K, Brown KS, Passmore PA, Craig D, McGuinness B, Todd S, Holmes C, Mann D, Smith AD, Love S, Kehoe PG, Hardy J, Mead S, Fox N, Rossor M, Collinge J, Maier W, Jessen F, Schurmann B, van den Bussche H, Heuser I, Kornhuber J, Wiltfang J, Dichgans M, Frolich L, Hampel H, Hull M, Rujescu D, Goate AM, Kauwe JS, Cruchaga C, Nowotny P, Morris JC, Mayo K, Sleegers K, Bettens K, Engelborghs S, De Deyn PP, Van Broeckhoven C, Livingston G, Bass NJ, Gurling H, McQuillin A, Gwilliam R, Deloukas P, Al-Chalabi A, Shaw CE, Tsolaki M, Singleton AB, Guerreiro R, Muhleisen TW, Nothen MM, Moebus S, Jockel KH, Klopp N, Wichmann HE, Carrasquillo MM, Pankratz VS, Younkin SG, Holmans PA, O'Donovan M, Owen MJ, and Williams J. Genome-wide association study identifies variants at CLU and PICALM associated with Alzheimer's disease. Nat Genet 41: 1088-1093, 2009.
111. Hatanpaa K, Brady DR, Stoll J, Rapoport SI, and Chandrasekaran K. Neuronal activity and early neurofibrillary tangles in Alzheimer's disease. Ann Neurol 40: 411-420, 1996. (Pubitemid 26304798)
112. Hauptmann S, Scherping I, Drose S, Brandt U, Schulz KL, Jendrach M, Leuner K, Eckert A, and Muller WE. Mitochondrial dysfunction: An early event in Alzheimer pathology accumulates with age in AD transgenic mice. Neurobiol Aging 30: 1574-1586, 2009.
113. Hirai K, Aliev G, Nunomura A, Fujioka H, Russell RL, Atwood CS, Johnson AB, Kress Y, Vinters HV, Tabaton M, Shimohama S, Cash AD, Siedlak SL, Harris PL, Jones PK, Petersen RB, Perry G, and Smith MA. Mitochondrial abnormalities in Alzheimer's disease. J Neurosci 21: 3017-3023, 2001. (Pubitemid 32323483)
114. Hirsch T, Marzo I, and Kroemer G. Role of the mitochondrial permeability transition pore in apoptosis. Biosci Rep 17: 67-76, 1997. (Pubitemid 27267593)
115. Hockenbery D, Nunez G, Milliman C, Schreiber RD, and Korsmeyer SJ. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature 348: 334-336, 1990. (Pubitemid 120029101)
116. Hoglinger GU, Lannuzel A, Khondiker ME, Michel PP, Duyckaerts C, Feger J, Champy P, Prigent A, Medja F, Lombes A, Oertel WH, Ruberg M, and Hirsch EC. The mitochondrial complex I inhibitor rotenone triggers a cerebral tauopathy. J Neurochem 95: 930-939, 2005. (Pubitemid 41713479)
117. Holt IJ. Zen and the art of mitochondrial DNA maintenance. Trends Genet 26: 103-109, 2010.
118. Honea RA, Swerdlow RH, Vidoni E, and Burns JM. Progressive regional atrophy in normaladults with a maternal history of Alzheimer disease. Neurology 76: 822-829, 2011.
119. Honea RA, Swerdlow RH, Vidoni ED, Goodwin J, and Burns JM. Reduced gray matter volume in normal adults with a maternal family history of Alzheimer disease. Neurology 74: 113-120, 2010.
120. Hoyer S. Brain oxidative energy and related metabolism, neuronal stress, and Alzheimer's disease: A speculative synthesis. J Geriatr Psychiatry Neurol 6: 3-13, 1993. (Pubitemid 23050674)
121. Hoyer S. Brain glucose and energy metabolism abnormalities in sporadic Alzheimer disease. Causes and consequences: An update. Exp Gerontol 35: 1363-1372, 2000.
122. Hutchin T and Cortopassi G. A mitochondrial DNA clone is associated with increased risk for Alzheimer disease. Proc Natl Acad Sci USA 92: 6892-6895, 1995.
123. Ienco EC, Simoncini C, Orsucci D, Petrucci L, Filosto M, Mancuso M, and Siciliano G. May "mitochondrial eve" and mitochondrial haplogroups play a role in neurodegeneration and Alzheimer's disease? Int J Alzheimers Dis 2011: 709061, 2011.
124. Ito E, Oka K, Etcheberrigaray R, Nelson TJ, McPhie DL, Tofel-Grehl B, Gibson GE, and Alkon DL. Internal Ca2 + mobilization is altered in fibroblasts from patients with Alzheimer disease. Proc Natl Acad Sci USA 91: 534-538, 1994.
125. Ito S, Ohta S, Nishimaki K, Kagawa Y, Soma R, Kuno SY, Komatsuzaki Y, Mizusawa H, and Hayashi J. Functional integrity of mitochondrial genomes in human platelets and autopsied brain tissues from elderly patients with Alzheimer's disease. Proc Natl Acad Sci USA 96: 2099-2103, 1999. (Pubitemid 29117874)
126. Iwangoff P, Armbruster R, Enz A,and Meier-Ruge W. Glycolytic enzymes from human autoptic brain cortex: Normal aged and demented cases. Mech Ageing Dev 14: 203-209, 1980. (Pubitemid 11175996)
127. Jia Z and Misra HP. Reactive oxygen species in in vitro pesticide-induced neuronal cell (SH-SY5Y) cytotoxicity: Role of NFkappaB and caspase-3. Free Radic Biol Med 42: 288-298, 2007. (Pubitemid 46001553)
128. Johnson AB and Blum NR. Nucleoside phosphatase activities associated with the tangles and plaques ofAlzheimer's disease: A histochemical study of natural and experimental neurofibrillary tangles. J Neuropathol Exp Neurol 29: 463-478, 1970.
129. Jope RS. Cholinergic muscarinic receptor signaling by the phosphoinositide signal transduction system in Alzheimer's disease. J Alzheimers Dis 1: 231-247, 1999.
130. Jorm AF and Jolley D. The incidence of dementia: A metaanalysis. Neurology 51: 728-733, 1998.
131. Jun G, Naj AC, Beecham GW, Wang LS, Buros J, Gallins PJ, Buxbaum JD, Ertekin-Taner N, Fallin MD, Friedland R, Inzelberg R, Kramer P, Rogaeva E, St George-Hyslop P, Cantwell LB, Dombroski BA, Saykin AJ, Reiman EM, Bennett DA, Morris JC, Lunetta KL, Martin ER, Montine TJ, Goate AM, Blacker D, Tsuang DW, Beekly D, Cupples LA, Hakonarson H, Kukull W, Foroud TM, Haines J, Mayeux R, Farrer LA, Pericak-Vance MA, and Schellenberg GD. Metaanalysis confirms CR1, CLU, and PICALM as Alzheimer disease risk loci and reveals interactions with APOE genotypes. Arch Neurol 67: 1473-1484, 2010.
132. Kaltschmidt B, Uherek M, Volk B, Baeuerle PA, and Kaltschmidt C. Transcription factor NF-kappaB is activated in primary neurons by amyloid beta peptides and in neurons surrounding early plaques from patients with Alzheimer disease. Proc Natl Acad Sci USA 94: 2642-2647, 1997. (Pubitemid 27136929)
133. Kamata H and Hirata H. Redox regulation of cellular signalling. Cell Signal 11: 1-14, 1999. (Pubitemid 28546635)
134. Kang D, Kim SH, and Hamasaki N. Mitochondrial transcription factor A (TFAM): roles in maintenance of mtDNA and cellular functions. Mitochondrion 7: 39-44, 2007. (Pubitemid 46351974)
135. Kang J, Lemaire HG, Unterbeck A, Salbaum JM, Masters CL, Grzeschik KH, Multhaup G, Beyreuther K, and Muller-Hill B. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor. Nature 325: 733-736, 1987. (Pubitemid 17054046)
136. Kang JE, Lim MM, Bateman RJ, Lee JJ, Smyth LP, Cirrito JR, Fujiki N, Nishino S, and Holtzman DM. Amyloid-beta dynamics are regulated by orexin and the sleep-wake cycle. Science 326: 1005-1007, 2009.
137. Katzman R. Alzheimer's disease. N Engl J Med 314: 964-973, 1986. (Pubitemid 16129832)
138. Keller JN. Interplay between oxidative damage, protein synthesis, and protein degradation in Alzheimer's disease. J Biomed Biotechnol 2006: 12129, 2006.
139. Keller JN, Schmitt FA, Scheff SW, Ding Q, Chen Q, Butterfield DA, and Markesbery WR. Evidence of increased oxidative damage in subjects with mild cognitive impairment. Neurology 64: 1152-1156, 2005.
140. Khachaturian ZS. Diagnosis of Alzheimer's disease. Arch Neurol 42: 1097-1105, 1985. (Pubitemid 16236926)
141. Khan SM, Cassarino DS, Abramova NN, Keeney PM, Borland MK, Trimmer PA, Krebs CT, Bennett JC, Parks JK, Swerdlow RH, Parker WD, Jr., and Bennett JP, Jr. Alzheimer's disease cybrids replicate beta-amyloid abnormalities through cell death pathways. Ann Neurol 48: 148-155, 2000. (Pubitemid 30617032)
142. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, and Gottesman MM. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528, 2007. (Pubitemid 46175758)
143. King MP and Attardi G. Human cells lacking mtDNA: Repopulation with exogenous mitochondria by complementation. Science 246: 500-503, 1989. (Pubitemid 19273941)
144. Kish SJ, Bergeron C, Rajput A, Dozic S, Mastrogiacomo F, Chang LJ, Wilson JM, DiStefano LM, and Nobrega JN. Brain cytochrome oxidase in Alzheimer's disease. J Neurochem 59: 776-779, 1992.
145. Kish SJ, Mastrogiacomo F, Guttman M, Furukawa Y, Taanman JW, Dozic S, Pandolfo M, Lamarche J, DiStefano L, and Chang LJ. Decreased brain protein levels of cytochrome oxidase subunits in Alzheimer's disease and in hereditary spinocerebellar ataxia disorders: A nonspecific change? J Neurochem 72: 700-707, 1999. (Pubitemid 29055233)
146. Komar AA, Guillemet E, Reiss C, and Cullin C. Enhanced expression of the yeast Ure2 protein in Escherichia coli: The effect of synonymous codon substitutions at a selected place in the gene. Biol Chem 379: 1295-1300, 1998. (Pubitemid 28484449)
147. Komar AA, Lesnik T, and Reiss C. Synonymous codon substitutions affect ribosome traffic and protein folding during in vitro translation. FEBS Lett 462: 387-391, 1999.
148. Kroemer G, Petit P, Zamzami N, Vayssiere JL, and Mignotte B. The biochemistry of programmed cell death. FASEB J 9: 1277-1287, 1995.
149. Kujoth GC, Hiona A, Pugh TD, Someya S, Panzer K, Wohlgemuth SE, Hofer T, Seo AY, Sullivan R, Jobling WA, Morrow JD, Van Remmen H, Sedivy JM, Yamasoba T, Tanokura M, Weindruch R, Leeuwenburgh C, and Prolla TA. Mitochondrial DNA mutations, oxidative stress, and apoptosis in mammalian aging. Science 309: 481-484, 2005. (Pubitemid 40994689)
150. Kumar U, Dunlop DM, and Richardson JS. Mitochondria from Alzheimer's fibroblasts show decreased uptake of calcium and increased sensitivity to free radicals. Life Sci 54: 1855-1860, 1994. (Pubitemid 24170244)
151. Kusiak JW, Izzo JA, and Zhao B. Neurodegeneration in Alzheimer disease. Is apoptosis involved? Mol Chem Neuropathol 28: 153-162, 1996. (Pubitemid 26275063)
152. Lakatos A, Derbeneva O, Younes D, Keator D, Bakken T, Lvova M, Brandon M, Guffanti G, Reglodi D, Saykin A, Weiner M, Macciardi F, Schork N, Wallace DC, and Potkin SG. Association between mitochondrial DNA variations and Alzheimer's disease in the ADNI cohort. Neurobiol Aging 31: 1355-1363, 2010.
153. Lambert JC, Heath S, Even G, Campion D, Sleegers K, Hiltunen M, Combarros O, Zelenika D, Bullido MJ, Tavernier B, Letenneur L, Bettens K, Berr C, Pasquier F, Fievet N, Barberger-Gateau P, Engelborghs S, De Deyn P, Mateo I, Franck A, Helisalmi S, Porcellini E, Hanon O, de Pancorbo MM, Lendon C, Dufouil C, Jaillard C, Leveillard T, Alvarez V, Bosco P, Mancuso M, Panza F, Nacmias B, Bossu P, Piccardi P, Annoni G, Seripa D, Galimberti D, Hannequin D, Licastro F, Soininen H, Ritchie K, Blanche H, Dartigues JF, Tzourio C, Gut I, Van Broeckhoven C, Alperovitch A, Lathrop M, and Amouyel P. Genome-wide association study identifies variants at CLU and CR1 associated with Alzheimer's disease. Nat Genet 41: 1094-1099, 2009.
154. Levy-Lahad E, Wasco W, Poorkaj P, Romano DM, Oshima J, Pettingell WH, Yu CE, Jondro PD, Schmidt SD, Wang K, et al. Candidate gene for the chromosome 1 familial Alzheimer's disease locus. Science 269: 973-977, 1995.
155. Li F, Calingasan NY, Yu F, Mauck WM, Toidze M, Almeida CG, Takahashi RH, Carlson GA, Flint Beal M, Lin MT, and Gouras GK. Increased plaque burden in brains of APP mutant MnSOD heterozygous knockout mice. J Neurochem 89: 1308-1312, 2004. (Pubitemid 38715849)
156. Li X, Song L, and Jope RS. Cholinergic stimulation of AP-1 and NF kappa B transcription factors is differentially sensitive to oxidative stress in SH-SY5Y neuroblastoma: Relationship to phosphoinositide hydrolysis. J Neurosci 16: 5914-5922, 1996. (Pubitemid 26313967)
157. Lin MT and Beal MF. Alzheimer's APP mangles mitochondria. Nat Med 12: 1241-1243, 2006. (Pubitemid 44706922)
158. Lin MT, Simon DK, Ahn CH, Kim LM, and Beal MF. High aggregate burden of somatic mtDNA point mutations in aging and Alzheimer's disease brain. Hum Mol Genet 11: 133-145, 2002. (Pubitemid 34157005)
159. Liu Y, Liu F, Grundke-Iqbal I, Iqbal K, and Gong CX. Deficient brain insulin signalling pathway in Alzheimer's disease and diabetes. J Pathol 225: 54-62, 2011.
160. Lovell MA, Ehmann WD, Butler SM, and Markesbery WR. Elevated thiobarbituric acid-reactive substances and antioxidant enzyme activity in the brain in Alzheimer's disease. Neurology 45: 1594-1601, 1995.
161. Lu J, Wang K, Rodova M, Esteves R, Berry D, E L, Crafter A, Barrett M, Cardoso SM, Onyango I, Parker WD, Fontes J, Burns JM, and Swerdlow RH. Polymorphic variation in cytochrome oxidase subunit genes. J Alzheimers Dis 21: 141-154, 2010.
162. Lustbader JW, Cirilli M, Lin C, Xu HW, Takuma K, Wang N, Caspersen C, Chen X, Pollak S, Chaney M, Trinchese F, Liu S, Gunn-Moore F, Lue LF, Walker DG, Kuppusamy P, Zewier ZL, Arancio O, Stern D, Yan SS, and Wu H. ABAD directly links Abeta to mitochondrial toxicity in Alzheimer's disease. Science 304: 448-452, 2004. (Pubitemid 38495942)
163. Magistretti PJ and Pellerin L. Cellular mechanisms of brain energy metabolism and their relevance to functional brain imaging. Philos Trans R Soc Lond B Biol Sci 354: 1155-1163, 1999. (Pubitemid 29400898)
164. Maliarchuk BA and Derenko MV. [T4336C variant-A marker of mitochondrial subgroup H1, a common component of the Russian and German gene pool]. Genetika 37: 1578-1580, 2001. (Pubitemid 33770694)
165. Mancuso M, Filosto M, Bosetti F, Ceravolo R, Rocchi A, Tognoni G, Manca ML, Solaini G, Siciliano G, and Murri L. Decreased platelet cytochrome c oxidase activity is accompanied by increased blood lactate concentration during exercise in patients with Alzheimer disease. Exp Neurol 182: 421-426, 2003. (Pubitemid 36937094)
166. Mancuso M, Siciliano G, Filosto M, and Murri L. Mitochondrial dysfunction and Alzheimer's disease: New developments. J Alzheimers Dis 9: 111-117, 2006. (Pubitemid 44078639)
167. Manczak M, Anekonda TS, Henson E, Park BS, Quinn J, and Reddy PH. Mitochondria are a direct site of A beta accumulation in Alzheimer's disease neurons: Implications for free radical generation and oxidative damage in disease progression. Hum Mol Genet 15: 1437-1449, 2006.
168. Manczak M, Calkins MJ, and Reddy PH. Impaired mitochondrial dynamics and abnormal interaction of amyloid beta with mitochondrial protein Drp1 in neurons from patients with Alzheimer's disease: Implications for neuronal damage. Hum Mol Genet 220: 2495-2509, 2011.
169. Manczak M, Park BS, Jung Y, and Reddy PH. Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: Implications for early mitochondrial dysfunction and oxidative damage. Neuromolecular Med 5: 147-162, 2004. (Pubitemid 38596548)
170. Markesbery WR. The role of oxidative stress in Alzheimer disease. Arch Neurol 56: 1449-1452, 1999.
171. Martinez-Redondo D, Marcuello A, Casajus JA, Ara I, Dahmani Y, Montoya J, Ruiz-Pesini E, Lopez-Perez MJ, and Diez-Sanchez C. Human mitochondrial haplogroup H: the highest VO2max consumer-Is it a paradox? Mitochondrion 10: 102-107, 2010.
172. Martins RN, Harper CG, Stokes GB, and Masters CL. Increased cerebral glucose-6-phosphate dehydrogenase activity in Alzheimer's disease may reflect oxidative stress. J Neurochem 46: 1042-1045, 1986. (Pubitemid 16010948)
173. Maruszak A, Canter JA, Styczynska M, Zekanowski C, and Barcikowska M. Mitochondrial haplogroup H and Alzheimer's disease-Is there a connection? Neurobiol Aging 30: 1749-1755, 2009.
174. Maruszak A, Safranow K, W. B, Gaweda-Walerych K, Pospiech E, Gabryelewicz T, Canter JA, Barcikowska M, and Zekanowski C. The impact of mitochondrial and nuclear DNA variants in late-onset Alzheimer's disease risk. JAD, in press.
175. Masliah E, Cole GM, Hansen LA, Mallory M, Albright T, Terry RD, and Saitoh T. Protein kinase C alteration is an early biochemical marker in Alzheimer's disease. J Neurosci 11: 2759-2767, 1991.
176. Maurer I, Zierz S, and Moller HJ. A selective defect of cytochrome c oxidase is present in brain of Alzheimer disease patients. Neurobiol Aging 21: 455-462, 2000. (Pubitemid 30349116)
177. McKhann G, Drachman D, Folstein M, Katzman R, Price D, and Stadlan EM. Clinical diagnosis of Alzheimer's disease: Report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 34: 939-944, 1984. (Pubitemid 14076461)
178. McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR, Jr., Kawas CH, Klunk WE, Koroshetz WJ, Manly JJ, Mayeux R, Mohs RC, Morris JC, Rossor MN, Scheltens P, Carrillo MC, Thies B, Weintraub S, and Phelps CH. The diagnosis of dementia due to Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer'sAssociationworkgroups ondiagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 263-269, 2011.
179. Mecocci P, MacGarvey U, and Beal MF. Oxidative damage to mitochondrial DNA is increased in Alzheimer's disease. Ann Neurol 36: 747-751, 1994. (Pubitemid 24337634)
180. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, and Berg L. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41: 479-486, 1991.
181. Morais R, Desjardins P, Turmel C, and Zinkewich-Peotti K. Development and characterization of continuous avian cell lines depleted of mitochondrial DNA. In Vitro Cell Dev Biol 24: 649-658, 1988.
182. Moreira PI, Carvalho C, Zhu X, Smith MA, and Perry G. Mitochondrial dysfunction is a trigger of Alzheimer's disease pathophysiology. Biochim Biophys Acta 1802: 2-10, 2010.
183. Mosconi L, Berti V, Swerdlow RH, Pupi A, Duara R, and de Leon M. Maternal transmission of Alzheimer's disease: Prodromal metabolic phenotype and the search for genes. Hum Genomics 4: 170-193, 2010.
184. Mosconi L, Brys M, Switalski R, Mistur R, Glodzik L, Pirraglia E, Tsui W, De Santi S, and de Leon MJ. Maternal family history of Alzheimer's disease predisposes to reduced brain glucose metabolism. Proc Natl Acad Sci USA 104: 19067-19072, 2007.
185. Mosconi L, de Leon M, Murray J, E L, Lu J, Javier E, McHugh P, and Swerdlow RH. Reduced mitochondria cytochrome oxidase activity in adult children of mothers with Alzheimer's disease. JAD [Epub ahead of print, 2011].
186. Mosconi L, Glodzik L, Mistur R, McHugh P, Rich KE, Javier E, Williams S, Pirraglia E, De Santi S, Mehta PD, Zinkowski R, Blennow K, Pratico D, and de Leon MJ. Oxidative stress and amyloid-beta pathology in normal individuals with a maternal history of Alzheimer's. Biol Psychiatry 68: 913-921, 2010.
187. Mosconi L, Mistur R, Switalski R, Brys M, Glodzik L, Rich K, Pirraglia E, Tsui W, De Santi S, and de Leon MJ. Declining brain glucose metabolism in normal individuals with a maternal history of Alzheimer disease. Neurology 72: 513-520, 2009.
188. Mosconi L, Rinne JO, Tsui WH, Berti V, Li Y, Wang H, Murray J, Scheinin N, Nagren K, Williams S, Glodzik L, De Santi S, Vallabhajosula S, and de Leon MJ. Increased fibrillar amyloid-{beta} burden in normal individuals with a family history of late-onset Alzheimer's. Proc Natl Acad Sci USA 107: 5949-5954, 2010.
189. Mutisya EM, Bowling AC, and Beal MF. Cortical cytochrome oxidase activity is reduced in Alzheimer's disease. J Neurochem 63: 2179-2184, 1994. (Pubitemid 24369993)
190. Nagy Z, Esiri MM, LeGris M, and Matthews PM. Mitochondrial enzyme expression in the hippocampus in relation to Alzheimer-type pathology. Acta Neuropathol 97: 346-354, 1999. (Pubitemid 29134514)
191. Nakamura T, Watanabe A, Fujino T, Hosono T, and Michikawa M. Apolipoprotein E4 (1-272) fragment is associated with mitochondrial proteins and affects mitochondrial function in neuronal cells. Mol Neurodegener 4: 35, 2009.
192. Nakano H, Nakajima A, Sakon-Komazawa S, Piao JH, Xue X, and Okumura K. Reactive oxygen species mediate crosstalk between NF-kappaB and JNK. Cell Death Differ 13: 730-737, 2006.
193. Nunomura A, Perry G, Aliev G, Hirai K, Takeda A, Balraj EK, Jones PK, Ghanbari H, Wataya T, Shimohama S, Chiba S, Atwood CS, Petersen RB, and Smith MA. Oxidative damage is the earliest event in Alzheimer disease. J Neuropathol Exp Neurol 60: 759-767, 2001. (Pubitemid 32678256)
194. O'Barr S, Schultz J, and Rogers J. Expression of the protooncogene bcl-2 in Alzheimer's disease brain. Neurobiol Aging 17: 131-136, 1996.
195. Onyango IG, Ahn JY, Tuttle JB, Bennett JP, Jr., and Swerdlow RH. Nerve growth factor attenuates oxidant-induced beta-amyloid neurotoxicity in sporadic Alzheimer's disease cybrids. J Neurochem 114: 1605-1618, 2010.
196. Onyango IG, Bennett JP, Jr., and Tuttle JB. Endogenous oxidative stress in sporadic Alzheimer's disease neuronal cybrids reduces viability by increasing apoptosis through pro-death signaling pathways and is mimicked by oxidant exposure of control cybrids. Neurobiol Dis 19: 312-322, 2005. (Pubitemid 40552821)
197. Onyango IG, Tuttle JB, and Bennett JP, Jr. Altered intracellular signaling and reduced viability of Alzheimer's disease neuronal cybrids is reproduced by beta-amyloid peptide acting through receptor for advanced glycation end products (RAGE). Mol Cell Neurosci 29: 333-343, 2005. (Pubitemid 40725622)
198. Ott A, Stolk RP, van Harskamp F, Pols HA, Hofman A, and Breteler MM. Diabetes mellitus and the risk of dementia: The Rotterdam Study. Neurology 53: 1937-1942, 1999.
199. Pappolla MA, Omar RA, Kim KS, and Robakis NK. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am J Pathol 140: 621-628, 1992.
200. Parisi MA and Clayton DA. Similarity of human mitochondrial transcription factor 1 to high mobility group proteins. Science 252: 965-969, 1991. (Pubitemid 21917015)
201. Parker WD. Sporadic neurologic disease and the electron transport chain: A hypothesis. In: Proceedings of the 1989 Scientfic Meeting of the American Society for Neurological Investigation: New Developments in Neuromuscular Disease edited by Pascuzzi RM. Bloomington, Indiana: Indiana University Printing Services; 1990.
202. Parker WD, Jr., Boyson SJ, and Parks JK. Abnormalities of the electron transport chain in idiopathic Parkinson's disease. Ann Neurol 26: 719-23, 1989. (Pubitemid 20011004)
203. Parker WD, Jr., Filley CM, and Parks JK. Cytochrome oxidase deficiency in Alzheimer's disease. Neurology 40: 1302-1303, 1990. (Pubitemid 20244999)
204. Parker WD, Jr., Mahr NJ, Filley CM, Parks JK, Hughes D, Young DA, and Cullum CM. Reduced platelet cytochrome c oxidase activity in Alzheimer's disease. Neurology 44: 1086-1090, 1994. (Pubitemid 24188183)
205. Parker WD, Jr., Parks J, Filley CM, and Kleinschmidt-De-Masters BK. Electron transport chain defects in Alzheimer's disease brain. Neurology 44: 1090-1096, 1994. (Pubitemid 24188184)
206. Parker WD, Jr. and Parks JK. Cytochrome c oxidase in Alzheimer's disease brain: Purification and characterization. Neurology 45: 482-486, 1995.
207. Parks JK, Smith TS, Trimmer PA, Bennett JP, Jr., and Parker WD, Jr. Neurotoxic Abeta peptides increase oxidative stress in vivo through NMDA-receptor and nitric-oxide-synthase mechanisms, and inhibit complex IV activity and induce a mitochondrial permeability transition in vitro. J Neurochem 76: 1050-1056, 2001. (Pubitemid 32167378)
208. Pei JJ, Khatoon S, An WL, Nordlinder M, Tanaka T, Braak H, Tsujio I, Takeda M, Alafuzoff I, Winblad B, Cowburn RF, Grundke-Iqbal I, and Iqbal K. Role of protein kinase B in Alzheimer's neurofibrillary pathology. Acta Neuropathol 105: 381-392, 2003. (Pubitemid 36798832)
209. Pellerin L and Magistretti PJ. Glutamate uptake into astrocytes stimulates aerobic glycolysis: A mechanism coupling neuronal activity to glucose utilization. Proc Natl Acad Sci USA 91: 10625-10629, 1994. (Pubitemid 24329051)
210. Pereira C, Santos MS, and Oliveira C. Mitochondrial function impairment induced by amyloid beta-peptide on PC12 cells. Neuroreport 9: 1749-1755, 1998. (Pubitemid 28289179)
211. Pericak-Vance MA, Bebout JL, Gaskell PC, Jr., Yamaoka LH, Hung WY, Alberts MJ, Walker AP, Bartlett RJ, Haynes CA, Welsh KA, et al. Linkage studies in familial Alzheimer disease: Evidence for chromosome 19 linkage. Am J Hum Genet 48: 1034-1050, 1991. (Pubitemid 21903065)
212. Perry EK, Perry RH, Tomlinson BE, Blessed G, and Gibson PH. Coenzyme A-acetylating enzymes in Alzheimer's disease: Possible cholinergic 'compartment' of pyruvate dehydrogenase. Neurosci Lett 18: 105-110, 1980. (Pubitemid 10122792)
213. Perry G, Nunomura A, Hirai K, Zhu X, Perez M, Avila J, Castellani RJ, Atwood CS, Aliev G, Sayre LM, Takeda A, and Smith MA. Is oxidative damage the fundamental pathogenic mechanism of Alzheimer's and other neurodegenerative diseases? Free Radic Biol Med 33: 1475-1479, 2002. (Pubitemid 35351590)
214. Peterson C, Gibson GE, and Blass JP. Altered calcium uptake in cultured skin fibroblasts from patients with Alzheimer's disease. N Engl J Med 312: 1063-1065, 1985. (Pubitemid 15114304)
215. Peterson C and Goldman JE. Alterations in calcium content and biochemical processes in cultured skin fibroblasts from aged and Alzheimer donors. Proc Natl Acad Sci USA 83: 2758-2762, 1986. (Pubitemid 16026964)
216. Petit PX, Lecoeur H, Zorn E, Dauguet C, Mignotte B, and Gougeon ML. Alterations in mitochondrial structure and function are early events of dexamethasone-induced thymocyte apoptosis. J Cell Biol 130: 157-167, 1995.
217. Potkin SG, Guffanti G, Lakatos A, Turner JA, Kruggel F, Fallon JH, Saykin AJ, Orro A, Lupoli S, Salvi E, Weiner M, and Macciardi F. Hippocampal atrophy as a quantitative trait in a genome-wide association study identifying novel susceptibility genes for Alzheimer's disease. PLoS One 4: e6501, 2009.
218. Reddy PH, McWeeney S, Park BS, Manczak M, Gutala RV, Partovi D, Jung Y, Yau V, Searles R, Mori M, and Quinn J. Gene expression profiles of transcripts in amyloid precursor protein transgenic mice: Up-regulation of mitochondrial metabolism and apoptotic genes is an early cellular change in Alzheimer's disease. Hum Mol Genet 13: 1225-1240, 2004. (Pubitemid 38877876)
219. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, and Cowburn RF. Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15: 955-959, 2004. (Pubitemid 38591242)
220. Rodriguez-Santiago B, Casademont J, and Nunes V. Is mitochondrial DNA depletion involved in Alzheimer's disease? Eur J Hum Genet 9: 279-285, 2001. (Pubitemid 32366696)
221. Rodriguez Santiago B, Casademont J, and Nunes V. [Is there a relation between Alzheimer s disease and defects of mitochondrial DNA?]. Rev Neurol 33: 301-305, 2001. (Pubitemid 32971525)
222. Rohn TT, Head E, Su JH, Anderson AJ, Bahr BA, Cotman CW, and Cribbs DH. Correlation between caspase activation and neurofibrillary tangle formation in Alzheimer's disease. Am J Pathol 158: 189-198, 2001. (Pubitemid 32096484)
223. Roses AD. An inherited variable poly-T repeat genotype in TOMM40 in Alzheimer disease. Arch Neurol 67: 536-541, 2010.
224. Roses AD, Lutz MW, Amrine-Madsen H, Saunders AM, Crenshaw DG, Sundseth SS, Huentelman MJ, Welsh-Bohmer KA, and Reiman EM. A TOMM40 variable-length polymorphism predicts the age of late-onset Alzheimer's disease. Pharmacogenomics J 10: 375-384, 2010.
225. Roses AD, Saunders AM, Huang Y, Strum J, Weisgraber KH, and Mahley RW. Complex disease-associated pharmacogenetics: Drug efficacy, drug safety, and confirmation of a pathogenetic hypothesis (Alzheimer's disease). Pharmacogenomics J 7: 10-28, 2007. (Pubitemid 46322076)
226. Salehi A, Verhaagen J, Dijkhuizen PA, and Swaab DF. Colocalization of high-affinity neurotrophin receptors in nucleus basalis of Meynert neurons and their differential reduction in Alzheimer's disease. Neuroscience 75: 373-387, 1996. (Pubitemid 26361330)
227. Santoro A, Balbi V, Balducci E, Pirazzini C, Rosini F, Tavano F, Achilli A, Siviero P, Minicuci N, Bellavista E, Mishto M, Salvioli S, Marchegiani F, Cardelli M, Olivieri F, Nacmias B, Chiamenti AM, Benussi L, Ghidoni R, Rose G, Gabelli C, Binetti G, Sorbi S, Crepaldi G, Passarino G, Torroni A, and Franceschi C. Evidence for sub-haplogroup h5 of mitochondrial DNA as a risk factor for late onset Alzheimer's disease. PLoS One 5: e12037, 2010.
228. Satoh T, Nakatsuka D, Watanabe Y, Nagata I, Kikuchi H, and Namura S. Neuroprotection by MAPK/ERK kinase inhibition with U0126 against oxidative stress in a mouse neuronal cell line and rat primary cultured cortical neurons. Neurosci Lett 288: 163-166, 2000. (Pubitemid 30392436)
229. Schreck R, Albermann K, and Baeuerle PA. Nuclear factor kappa B: An oxidative stress-responsive transcription factor of eukaryotic cells (a review). Free Radic Res Commun 17: 221-237, 1992. (Pubitemid 23207431)
230. Schreck R, Rieber P, and Baeuerle PA. Reactive oxygen intermediates as apparently widely used messengers in the activation of the NF-κ B transcription factor and HIV. EMBO J 10: 2247-2258, 1991. (Pubitemid 21905698)
231. Selznick LA, Holtzman DM, Han BH, Gokden M, Srinivasan AN, Johnson EM, Jr., and Roth KA. In situ immunodetection of neuronal caspase-3 activation in Alzheimer disease. J Neuropathol Exp Neurol 58: 1020-1026, 1999. (Pubitemid 29441930)
232. Seshadri S, Fitzpatrick AL, Ikram MA, DeStefano AL, Gudnason V, Boada M, Bis JC, Smith AV, Carassquillo MM, Lambert JC, Harold D, Schrijvers EM, Ramirez-Lorca R, Debette S, Longstreth WT, Jr., Janssens AC, Pankratz VS, Dartigues JF, Hollingworth P, Aspelund T, Hernandez I, Beiser A, Kuller LH, Koudstaal PJ, Dickson DW, Tzourio C, Abraham R, Antunez C, Du Y, Rotter JI, Aulchenko YS, Harris TB, Petersen RC, Berr C, Owen MJ, Lopez-Arrieta J, Varadarajan BN, Becker JT, Rivadeneira F, Nalls MA, Graff-Radford NR, Campion D, Auerbach S, Rice K, Hofman A, Jonsson PV, Schmidt H, Lathrop M, Mosley TH, Au R, Psaty BM, Uitterlinden AG, Farrer LA, Lumley T, Ruiz A, Williams J, Amouyel P, Younkin SG, Wolf PA, Launer LJ, Lopez OL, van Duijn CM, and Breteler MM. Genomewide analysis of genetic loci associated with Alzheimer disease. JAMA 303: 1832-1840, 2010.
233. Sheehan JP, Swerdlow RH, Miller SW, Davis RE, Parks JK, Parker WD, and Tuttle JB. Calcium homeostasis and reactive oxygen species production in cells transformed by mitochondria from individuals with sporadic Alzheimer's disease. J Neurosci 17: 4612-4622, 1997. (Pubitemid 27246919)
234. Sheehan JP, Swerdlow RH, Parker WD, Miller SW, Davis RE, and Tuttle JB. Altered calcium homeostasis in cells transformed by mitochondria from individuals with Parkinson's disease. J Neurochem 68: 1221-1233, 1997. (Pubitemid 27086228)
235. Sherrington R, Rogaev EI, Liang Y, Rogaeva EA, Levesque G, Ikeda M, Chi H, Lin C, Li G, Holman K, et al. Cloning of a gene bearing missense mutations in early-onset familial Alzheimer's disease. Nature 375: 754-760, 1995.
236. Shimohama S, Narita M, Matsushima H, Kimura J, Kameyama M, Hagiwara M, Hidaka H, and Taniguchi T. Assessment of protein kinase C isozymes by two-site enzyme immunoassay in human brains and changes in Alzheimer's disease. Neurology 43: 1407-1413, 1993. (Pubitemid 23213819)
237. Shoffner JM, Brown MD, Torroni A, Lott MT, Cabell MF, Mirra SS, Beal MF, Yang CC, Gearing M, Salvo R, et al. Mitochondrial DNA variants observed in Alzheimer disease and Parkinson disease patients. Genomics 17: 171-184, 1993. (Pubitemid 23205074)
238. Silva DF, Esteves AR, Arduino DM, Oliveira CR, Cardoso SM. Amyloid-beta-induced mitochondrial dysfunction impairs the autophagic lysosomal pathway in a tubulin dependent pathway. J Alzheimers Dis in press, 2011.
239. Silva DFF, Esteves AR, Oliveira CR, and Cardoso SM. Mitochondria: The common upstream driver of amyloidbeta and tau pathology in Alzheimer's disease. Curr Alzheimer Res in press, 2011.
240. Simonian NA and Hyman BT. Functional alterations in Alzheimer's disease: Diminution of cytochrome oxidase in the hippocampal formation. J Neuropathol Exp Neurol 52: 580-585, 1993. (Pubitemid 23335733)
241. Sims NR, Finegan JM, and Blass JP. Altered glucose metabolism in fibroblasts from patients with Alzheimer's disease. N Engl J Med 313: 638-639, 1985. (Pubitemid 15012944)
242. Sims NR, Finegan JM, and Blass JP. Altered metabolic properties of cultured skin fibroblasts in Alzheimer's disease. Ann Neurol 21: 451-457, 1987. (Pubitemid 17068544)
243. Sims NR, Finegan JM, Blass JP, Bowen DM, and Neary D. Mitochondrial function in brain tissue in primary degenerative dementia. Brain Res 436: 30-38, 1987. (Pubitemid 17167132)
244. Smale G, Nichols NR, Brady DR, Finch CE, and Horton WE, Jr. Evidence for apoptotic cell death in Alzheimer's disease. Exp Neurol 133: 225-230, 1995.
245. Smith MA, Kutty RK, Richey PL, Yan SD, Stern D, Chader GJ, Wiggert B, Petersen RB, and Perry G. Heme oxygenase-1 is associated with the neurofibrillary pathology of Alzheimer's disease. Am J Pathol 145: 42-47, 1994. (Pubitemid 24217481)
246. Smith MA, Rudnicka-Nawrot M, Richey PL, Praprotnik D, Mulvihill P, Miller CA, Sayre LM, and Perry G. Carbonylrelated posttranslational modification of neurofilament protein in the neurofibrillary pathology of Alzheimer's disease. J Neurochem 64: 2660-2666, 1995.
247. Sorbi S, Bird ED, and Blass JP. Decreased pyruvate dehydrogenase complex activity in Huntington and Alzheimer brain. Ann Neurol 13: 72-78, 1983. (Pubitemid 13224203)
248. Sperling RA, Aisen PS, Beckett LA, Bennett DA, Craft S, Fagan AM, Iwatsubo T, Jack CR, Jr., Kaye J, Montine TJ, Park DC, Reiman EM, Rowe CC, Siemers E, Stern Y, Yaffe K, Carrillo MC, Thies B, Morrison-Bogorad M, Wagster MV, and Phelps CH. Toward defining the preclinical stages of Alzheimer's disease: Recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 7: 280-292, 2011.
249. Strazielle C, Jazi R, Verdier Y, Qian S, and Lalonde R. Regional brain metabolism with cytochrome c oxidase histochemistry in a PS1/A246E mouse model of autosomal dominant Alzheimer's disease: Correlations with behavior and oxidative stress. Neurochem Int 55: 806-814, 2009.
250. Su B, Wang X, Nunomura A, Moreira PI, Lee HG, Perry G, Smith MA, and Zhu X. Oxidative stress signaling in Alzheimer's disease. Curr Alzheimer Res 5: 525-532, 2008.
251. Su JH, Anderson AJ, Cummings BJ, and Cotman CW. Immunohistochemical evidence for apoptosis in Alzheimer's disease. Neuroreport 5: 2529-2533, 1994.
252. Su JH, Deng G, and Cotman CW. Bax protein expression is increased in Alzheimer's brain: Correlations with DNA damage, Bcl-2 expression, and brain pathology. J Neuropathol Exp Neurol 56: 86-93, 1997. (Pubitemid 127470330)
253. Suzuki A, Stern SA, Bozdagi O, Huntley GW, Walker RH, Magistretti PJ, and Alberini CM. Astrocyte-neuron lactate transport is required for long-term memory formation. Cell 144: 810-823, 2011.
254. Suzuki K and Terry RD. Fine structural localization of acid phosphatase in senile plaques in Alzheimer's presenile dementia. Acta Neuropathol 8: 276-284, 1967.
255. Swerdlow R, Marcus DL, Landman J, Kooby D, Frey W, 2nd, and Freedman ML. Brain glucose metabolism in Alzheimer's disease. Am J Med Sci 308: 141-144, 1994. (Pubitemid 24323396)
256. Swerdlow RH. Is aging part of Alzheimer's disease, or is Alzheimer's disease part of aging? Neurobiol Aging 28: 1465-1480, 2007. (Pubitemid 47238532)
257. Swerdlow RH. Mitochondria in cybrids containing mtDNA from persons with mitochondriopathies. J Neurosci Res 85: 3416-3428, 2007. (Pubitemid 350058530)
258. Swerdlow RH. Pathogenesis of Alzheimer's disease. Clin Interv Aging 2: 347-359, 2007.
259. Swerdlow RH. The neurodegenerative mitochondriopathies. J Alzheimers Dis 17: 737-751, 2009.
260. Swerdlow RH, Burns JM, and Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis. J Alzheimers Dis 20: S265-279, 2010.
261. Swerdlow RH and Khan SM. A "mitochondrial cascade hypothesis" for sporadic Alzheimer's disease. Med Hypotheses 63: 8-20, 2004. (Pubitemid 38887104)
262. Swerdlow RH and Khan SM. The Alzheimer's disease mitochondrial cascade hypothesis: An update. Exp Neurol 218: 308-315, 2009.
263. Swerdlow RH and Kish SJ. Mitochondria in Alzheimer's disease. Int Rev Neurobiol 53: 341-385, 2002.
264. Swerdlow RH, Parks JK, Cassarino DS, Maguire DJ, Maguire RS, Bennett JP, Jr., Davis RE, and Parker WD, Jr. Cybrids in Alzheimer's disease: A cellular model of the disease? Neurology 49: 918-925, 1997. (Pubitemid 27456066)
265. Szabados T, Dul C, Majtenyi K, Hargitai J, Penzes Z, and Urbanics R. A chronic Alzheimer's model evoked by mitochondrial poison sodium azide for pharmacological investigations. Behav Brain Res 154: 31-40, 2004. (Pubitemid 39070450)
266. Takasaki S. Mitochondrial haplogroups associated with Japanese Alzheimer's patients. J Bioenerg Biomembr 41: 407-410, 2009.
267. Takei N, Miyashita A, Tsukie T, Arai H, Asada T, Imagawa M, Shoji M, Higuchi S, Urakami K, Kimura H, Kakita A, Takahashi H, Tsuji S, Kanazawa I, Ihara Y, Odani S, and Kuwano R. Genetic association study on in and around the APOE in late-onset Alzheimer disease in Japanese. Genomics 93: 441-448, 2009.
268. Tamagno E, Bardini P, Obbili A, Vitali A, Borghi R, Zaccheo D, Pronzato MA, Danni O, Smith MA, Perry G, and Tabaton M. Oxidative stress increases expression and activity of BACE in NT2 neurons. Neurobiol Dis 10: 279-288, 2002. (Pubitemid 35217581)
269. Tamagno E, Guglielmotto M, Giliberto L, Vitali A, Borghi R, Autelli R, Danni O, and Tabaton M. JNK and ERK1/2 pathways have a dual opposite effect on the expression of BACE1. Neurobiol Aging 30: 1563-1573, 2009.
270. Tanaka N, Goto Y, Akanuma J, Kato M, Kinoshita T, Yamashita F, Tanaka M, and Asada T. Mitochondrial DNA variants in a Japanese population of patients with Alzheimer's disease. Mitochondrion 10: 32-37, 2010.
271. Teng FY and Tang BL. Widespread gamma-secretase activity in the cell, but do we need it at the mitochondria? Biochem Biophys Res Commun 328: 1-5, 2005. (Pubitemid 40164626)
272. Thiffault C and Bennett JP, Jr. Cyclical mitochondrial deltapsiM fluctuations linked to electron transport, F0F1 ATPsynthase and mitochondrial Na +Ca + 2 exchange are reduced in Alzheimer's disease cybrids. Mitochondrion 5: 109-119, 2005. (Pubitemid 40485770)
273. Tortosa A, Lopez E, and Ferrer I. Bcl-2 and Bax protein expression in Alzheimer's disease. Acta Neuropathol 95: 407-412, 1998. (Pubitemid 28142550)
274. Trifunovic A, Wredenberg A, Falkenberg M, Spelbrink JN, Rovio AT, Bruder CE, Bohlooly YM, Gidlof S, Oldfors A, Wibom R, Tornell J, Jacobs HT, and Larsson NG. Premature ageing in mice expressing defective mitochondrial DNA polymerase. Nature 429: 417-423, 2004. (Pubitemid 38715133)
275. Trimmer PA and Borland MK. Differentiated Alzheimer's disease transmitochondrial cybrid cell lines exhibit reduced organelle movement. Antioxid Redox Signal 7: 1101-1109, 2005. (Pubitemid 41232506)
276. Trimmer PA, Keeney PM, Borland MK, Simon FA, Almeida J, Swerdlow RH, Parks JP, Parker WD, Jr., and Bennett JP, Jr. Mitochondrial abnormalities in cybrid cell models of sporadic Alzheimer's disease worsen with passage in culture. Neurobiol Dis 15: 29-39, 2004. (Pubitemid 38134378)
277. Trimmer PA, Swerdlow RH, Parks JK, Keeney P, Bennett JP, Jr., Miller SW, Davis RE, and Parker WD, Jr. Abnormal mitochondrial morphology in sporadic Parkinson's and Alzheimer's disease cybrid cell lines. Exp Neurol 162: 37-50, 2000. (Pubitemid 30170099)
278. Tsujimoto Y and Shimizu S. Role of the mitochondrial membrane permeability transition in cell death. Apoptosis 12: 835-840, 2007. (Pubitemid 46653286)
279. Turner CJ, Granycome C, Hurst R, Pohler E, Juhola MK, Juhola MI, Jacobs HT, Sutherland L, and Holt IJ. Systematic segregation to mutant mitochondrial DNA and accompanying loss of mitochondrial DNA in human NT2 teratocarcinoma cybrids. Genetics 170: 1879-1885, 2005. (Pubitemid 41362839)
280. Valla J, Berndt JD, and Gonzalez-Lima F. Energy hypometabolism in posterior cingulate cortex of Alzheimer's patients: Superficial laminar cytochrome oxidase associated with disease duration. J Neurosci 21: 4923-4930, 2001. (Pubitemid 32565651)
281. Valla J, Schneider L, Niedzielko T, Coon KD, Caselli R, Sabbagh MN, Ahern GL, Baxter L, Alexander G, Walker DG, and Reiman EM. Impaired platelet mitochondrial activity in Alzheimer's disease and mild cognitive impairment. Mitochondrion 6: 323-330, 2006. (Pubitemid 44817367)
282. Valla J, Yaari R, Wolf AB, Kusne Y, Beach TG, Roher AE, Corneveaux JJ, Huentelman MJ, Caselli RJ, and Reiman EM. Reduced posterior cingulate mitochondrial activity in expired young adult carriers of the APOE epsilon4 allele, the major late-onset Alzheimer's susceptibility gene. J Alzheimers Dis 22: 307-313, 2010.
283. van der Walt JM, Dementieva YA, Martin ER, Scott WK, Nicodemus KK, Kroner CC, Welsh-Bohmer KA, Saunders AM, Roses AD, Small GW, Schmechel DE, Murali Doraiswamy P, Gilbert JR, Haines JL, Vance JM, and Pericak-Vance MA. Analysis of European mitochondrial haplogroups with Alzheimer disease risk. Neurosci Lett 365: 28-32, 2004. (Pubitemid 38952729)
284. Verwer RW, Jansen KA, Sluiter AA, Pool CW, Kamphorst W, and Swaab DF. Decreased hippocampal metabolic activity in Alzheimer patients is not reflected in the immunoreactivity of cytochrome oxidase subunits. Exp Neurol 163: 440-451, 2000. (Pubitemid 30399094)
285. Wallace DC. Mitochondrial genetics: A paradigm for aging and degenerative diseases? Science 256: 628-632, 1992.
286. Wallace DC, Bunn CL, and Eisenstadt JM. Cytoplasmic transfer of chloramphenicol resistance in human tissue culture cells. J Cell Biol 67: 174-188, 1975.
287. Wang X, Su B, Fujioka H, and Zhu X. Dynamin-like protein 1 reduction underlies mitochondrial morphology and distribution abnormalities in fibroblasts from sporadic Alzheimer's disease patients. Am J Pathol 173: 470-482, 2008.
288. Wang X, Su B, Lee HG, Li X, Perry G, Smith MA, and Zhu X. Impaired balance of mitochondrial fission and fusion in Alzheimer's disease. J Neurosci 29: 9090-9103, 2009.
289. Wang X, Su B, Siedlak SL, Moreira PI, Fujioka H, Wang Y, Casadesus G, and Zhu X. Amyloid-beta overproduction causes abnormal mitochondrial dynamics via differential modulation of mitochondrial fission/fusion proteins. Proc Natl Acad Sci USA 105: 19318-19323, 2008.
290. Webster MT, Pearce BR, Bowen DM, and Francis PT. The effects of perturbed energy metabolism on the processing of amyloid precursor protein in PC12 cells. J Neural Transm 105: 839-853, 1998. (Pubitemid 28539833)
291. Wisniewski H, Terry RD, and Hirano A. Neurofibrillary pathology. J Neuropathol Exp Neurol 29: 163-176, 1970.
292. Wong-Riley M, Antuono P, Ho KC, Egan R, Hevner R, Liebl W, Huang Z, Rachel R, and Jones J. Cytochrome oxidase in Alzheimer's disease: Biochemical, histochemical, and immunohistochemical analyses of the visual and other systems. Vision Res 37: 3593-3608, 1997. (Pubitemid 27491637)
293. Wong-Riley MT. Cytochrome oxidase: An endogenous metabolic marker for neuronal activity. Trends Neurosci 12: 94-101, 1989. (Pubitemid 19067056)
294. Wragg MA, Talbot CJ, Morris JC, Lendon CL, Goate AM. No association found between Alzheimer's disease and a mitochondrial tRNA glutamine gene variant. Neurosci Lett 201: 107-110, 1995.
295. Yaffe K, Middleton LE, Lui LY, Spira AP, Stone K, Racine C, Ensrud KE, Kramer JH. Mild cognitive impairment, dementia, and their subtypes in oldest old women. Arch Neurol 68: 631-636, 2011.
296. Yamaguchi H, Yamazaki T, Ishiguro K, Shoji M, Nakazato Y, Hirai S. Ultrastructural localization of Alzheimer amyloid beta/A4 protein precursor in the cytoplasm of neurons and senile plaque-associated astrocytes. Acta Neuropathol 85: 15-22, 1992.
297. Yanagisawa M, Planel E, Ishiguro K, Fujita SC. Starvation induces tau hyperphosphorylation in mouse brain: Implications for Alzheimer's disease. FEBS Lett 461: 329-333, 1999. (Pubitemid 29533357)
298. Yao J, Du H, Yan S, Fang F, Wang C, Lue LF, Guo L, Chen D, Stern DM, Gunn Moore FJ, Xi Chen J, Arancio O, Yan SS. Inhibition of amyloid-beta (Abeta) peptide-binding alcohol dehydrogenase-Abeta interaction reduces Abeta accumulation and improves mitochondrial function in a mouse model of Alzheimer's disease. J Neurosci 31: 2313-2320, 2011.
299. Yao J, Irwin RW, Zhao L, Nilsen J, Hamilton RT, and Brinton RD. Mitochondrial bioenergetic deficit precedes Alzheimer's pathology in female mouse model of Alzheimer's disease. Proc Natl Acad Sci USA 106: 14670-14675, 2009.
300. Yu CE, Seltman H, Peskind ER, Galloway N, Zhou PX, Rosenthal E, Wijsman EM, Tsuang DW, Devlin B, and Schellenberg GD. Comprehensive analysis of APOE and selected proximate markers for late-onset Alzheimer's disease: Patterns of linkage disequilibrium and disease/marker association. Genomics 89: 655-665, 2007. (Pubitemid 46719797)
301. Zamzami N, Marchetti P, Castedo M, Zanin C, Vayssiere JL, Petit PX, and Kroemer G. Reduction in mitochondrial potential constitutes an early irreversible step of programmed lymphocyte death in vivo. J Exp Med 181: 1661-1672, 1995.
302. Zhang H, Liu Y, Lao M, Ma Z, and Yi X. Puerarin protects Alzheimer's disease neuronal cybrids from oxidant-stress induced apoptosis by inhibiting pro-death signaling pathways. Exp Gerontol 46: 30-37, 2011.
303. Zhang Q, Yu JT, Wang P, Chen W, Wu ZC, Jiang H, and Tan L. Mitochondrial transcription factor A (TFAM) polymorphisms and risk of late-onset Alzheimer's disease in Han Chinese. Brain Res 1368: 355-360, 2011.
304. Zhu X, Castellani RJ, Takeda A, Nunomura A, Atwood CS, Perry G, and Smith MA. Differential activation of neuronal ERK, JNK/SAPK and p38 in Alzheimer disease: the 'two hit' hypothesis. Mech Ageing Dev 123: 39-46, 2001. (Pubitemid 32972257)
305. Zhu X, Raina AK, Rottkamp CA, Aliev G, Perry G, Boux H, and Smith MA. Activation and redistribution of c-jun N-terminal kinase/stress activated protein kinase in degenerating neurons in Alzheimer's disease. J Neurochem76: 435-441, 2001. (Pubitemid 32097021)
306. Zsurka G, Kalman J, Csaszar A, Rasko I, Janka Z, and Venetianer P. No mitochondrial haplotype was found to increase risk for Alzheimer's disease. Biol Psychiatry 44: 371-373, 1998. (Pubitemid 28445518)